Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Retlirafusp alfa + platinum chemotherapy as neoadjuvant therapy for resectable stage II–III NSCLC
ChiCTR2600128997Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa in non-small cell lung cancer (NSCLC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Major pathological response rate (MPR). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600128997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128997.